1. Home
  2. ECVT vs WGS Comparison

ECVT vs WGS Comparison

Compare ECVT & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ecovyst Inc.

ECVT

Ecovyst Inc.

N/A

Current Price

$10.39

Market Cap

1.3B

Sector

Industrials

ML Signal

N/A

Logo GeneDx Holdings Corp.

WGS

GeneDx Holdings Corp.

N/A

Current Price

$77.39

Market Cap

1.2B

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
ECVT
WGS
Founded
1935
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Major Chemicals
Retail: Computer Software & Peripheral Equipment
Sector
Industrials
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.2B
IPO Year
2017
2020

Fundamental Metrics

Financial Performance
Metric
ECVT
WGS
Price
$10.39
$77.39
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
7
Target Price
$14.00
$120.71
AVG Volume (30 Days)
1.2M
790.4K
Earning Date
05-05-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
62.37
EPS
0.11
N/A
Revenue
$723,515,000.00
$427,539,000.00
Revenue This Year
$29.07
$29.98
Revenue Next Year
$6.71
$25.92
P/E Ratio
$94.45
N/A
Revenue Growth
2.70
39.97
52 Week Low
$7.41
$32.21
52 Week High
$15.09
$170.87

Technical Indicators

Market Signals
Indicator
ECVT
WGS
Relative Strength Index (RSI) 30.59 63.03
Support Level $9.67 $56.36
Resistance Level $11.31 $96.34
Average True Range (ATR) 0.40 5.73
MACD -0.13 0.94
Stochastic Oscillator 14.52 77.27

Price Performance

Historical Comparison
ECVT
WGS

About ECVT Ecovyst Inc.

Ecovyst Inc is an integrated and provider of materials, specialty catalysts and services. Its products contribute to lower emissions and cleaner air, higher fuel efficiency and cleaner fuels, and key enablers to advance transition to clean energy. The company has one operating segment. The Company's single reportable segment, Ecoservices, derives its revenue through the sale of virgin and regenerated sulfuric acid products and services.

About WGS GeneDx Holdings Corp.

GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.

Share on Social Networks: